The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
Official Title: A Phase II, Open-Label Study of Ispinesib in Subjects With Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)
Study ID: NCT00085813
Brief Summary: This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously (IV), repeated once every 21 days. A patient may continue treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Scottsdale, Arizona, United States
GSK Investigational Site, Jacksonville, Florida, United States
GSK Investigational Site, Rochester, Minnesota, United States
GSK Investigational Site, Rochester, New York, United States
GSK Investigational Site, Greensboro, North Carolina, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Memphis, Tennessee, United States
GSK Investigational Site, Bruxelles, , Belgium
GSK Investigational Site, Edegem, , Belgium
GSK Investigational Site, Leuven, , Belgium
GSK Investigational Site, Sutton, Surrey, United Kingdom
Name: GSK Clinical Trials, MD
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR